ArticleBMC cancer2026
Clinical-genomic risk discordance and its impact on treatment selection in premenopausal women with node-positive hormone receptor-positive breast cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeThe 21-gene Oncotype DX Recurrence Score (RS) is widely used to guide adjuvant chemotherapy decisions in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. However, the clinical interpretation of RS remains challenging in premenopausal women with node-positive disease, where discordance between genomic and clinicopathological risk is frequently encountered. This study aimed to elucidate the determinants of clinical–genomic risk discordance and to clarify its impact on real-world treatment selection, with a specific focus on premenopausal node-positive patients.
methodsWe retrospectively analyzed 290 patients with HR+/HER2- breast cancer who underwent curative surgery and Oncotype DX testing between September 2023 and November 2025. Clinical risk was defined according to the St. Gallen criteria, and concordance or discordance was determined based on agreement or disagreement between clinical risk and RS. Logistic regression analyses were performed to identify predictors of discordance in the overall cohort and in node-positive patients. Treatment allocation was further examined in a predefined subgroup of 28 premenopausal patients with node-positive disease. Treatment strategies were categorized as chemotherapy plus endocrine therapy, endocrine therapy combined with systemic intensification (abemaciclib or S-1), or endocrine therapy alone.
resultsClinical–genomic risk discordance was observed in 123 patients (42.4%). In multivariable analysis of the overall cohort, larger tumor size (OR 8.33) and nodal positivity (OR 6.43) were independently associated with discordance, indicating a strong association with tumor burden. In contrast, among node-positive patients, premenopausal status (OR 0.18, p = 0.045) and high proliferative activity (Ki-67 > 20%; OR 4.81, p = 0.048) were independently associated with discordance, indicating a distinct biological pattern associated with proliferative activity in premenopausal disease. In the premenopausal node-positive subgroup, all concordant cases received intravenous chemotherapy, whereas discordant cases showed marked heterogeneity in treatment selection: chemotherapy in 2 patients (8.0%), endocrine therapy combined with targeted or fluoropyrimidine-based intensification strategies (including abemaciclib or S-1) in 11 patients (44.0%), and endocrine therapy alone in 12 patients (p < 0.001).
conclusionsClinical–genomic risk discordance is frequent in premenopausal women with node-positive hormone receptor-positive, HER2-negative breast cancer and is associated with distinct biological characteristics, including high proliferative activity. In real-world clinical practice, discordance was linked to substantial variation in adjuvant treatment selection, with many patients managed using endocrine-based strategies. These findings highlight the clinical relevance of integrating genomic and clinicopathological information in treatment decision-making and support the role of genomic assays as complementary tools for individualized therapy in this challenging population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.